Literature DB >> 23870798

Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.

Sheng-Yu Lee1, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzung Lieh Yeh, Yen Kuang Yang, Ru-Band Lu, Jau-Shyong Hong.   

Abstract

UNLABELLED: Memantine is a noncompetitive NMDA receptor antagonist. As an augmenting agent, it has an antidepressant-like and mood-stabilizing effect. Memantine also reduces binge eating episodes and weight. We investigated whether memantine added on to valproate (VPA) is more effective than VPA alone for treating BP-II depression and improving the patient's metabolic profile. This was a randomized, double-blind, controlled study. BP-II patients undergoing regular VPA treatments were randomly assigned to one of two groups: VPA plus either add-on [1] memantine (5 mg/day) (n = 62) or [2] placebo (n = 73) for 12 weeks. The Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) were used to evaluate clinical response. Height, weight, fasting serum glucose, fasting total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were followed regularly. Multiple linear regressions with generalized estimating equation methods were used to analyze the effects of memantine on clinical performance. There were no significant differences in pre- and post-treatment YMRS and HDRS scores between the VPA + memantine and VPA + placebo groups. Although there were no significant differences in the pre- and post-treatment values of most metabolic indices between the two groups, there was a significant increase of HDL-C (p = 0.009) in the VPA + memantine group compared with the VPA + placebo group. This increase remained significant even after controlling for body mass index (BMI) (p = 0.020). We conclude that add-on memantine plus VPA treatment of BP-II depression increases the blood level of HDL-C even in the absence of change in affective symptoms. TRIAL REGISTRATION: NCT01188148 (https://register.clinicaltrials.gov/), Trial date was from 1st August, 2008 to 31st July, 2012 in National Cheng Kung University and Tri-Service General Hospital.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar II disorder; HDL-C; Memantine; Treatment

Mesh:

Substances:

Year:  2013        PMID: 23870798      PMCID: PMC4786167          DOI: 10.1016/j.jpsychires.2013.06.017

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  63 in total

1.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

2.  Low cholesterol in erythrocyte membranes and high lipoperoxides in erythrocytes are the potential risk factors for cerebral hemorrhagic stroke in human.

Authors:  H H Chen; J F Zhou
Journal:  Biomed Environ Sci       Date:  2001-09       Impact factor: 3.118

3.  Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study.

Authors:  Lewis L Judd; Hagop S Akiskal; Pamela J Schettler; Jean Endicott; Andrew C Leon; David A Solomon; William Coryell; Jack D Maser; Martin B Keller
Journal:  Arch Gen Psychiatry       Date:  2005-12

4.  Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group.

Authors:  H S Akiskal; A M Djenderedjian; R H Rosenthal; M K Khani
Journal:  Am J Psychiatry       Date:  1977-11       Impact factor: 18.112

Review 5.  Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease.

Authors:  G Franceschini
Journal:  Am J Cardiol       Date:  2001-12-20       Impact factor: 2.778

Review 6.  Glutamate receptor genes: susceptibility factors in schizophrenia and depressive disorders?

Authors:  Hans H Schiffer
Journal:  Mol Neurobiol       Date:  2002-04       Impact factor: 5.590

7.  Recurrence of bipolar disorders and major depression. A life-long perspective.

Authors:  Jules Angst; Alex Gamma; Robert Sellaro; Philip W Lavori; Heping Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2003-10       Impact factor: 5.270

8.  The emerging epidemiology of hypomania and bipolar II disorder.

Authors:  J Angst
Journal:  J Affect Disord       Date:  1998-09       Impact factor: 4.839

9.  Memantine in the treatment of binge eating disorder: an open-label, prospective trial.

Authors:  Brian P Brennan; Jacqueline L Roberts; Kate V Fogarty; Karina A Reynolds; Jeffrey M Jonas; James I Hudson
Journal:  Int J Eat Disord       Date:  2008-09       Impact factor: 4.861

10.  An open-label, flexible-dose study of memantine in major depressive disorder.

Authors:  James M Ferguson; Richard N Shingleton
Journal:  Clin Neuropharmacol       Date:  2007 May-Jun       Impact factor: 1.592

View more
  10 in total

1.  A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.

Authors:  P S Chen; H H Chang; C-C Huang; C C Lee; S-Y Lee; S-L Chen; S-Y Huang; Y K Yang; R-B Lu
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

Review 2.  Memantine: New prospective in bipolar disorder treatment.

Authors:  Giulia Serra; Francesca Demontis; Francesca Serra; Lavinia De Chiara; Andrea Spoto; Paolo Girardi; Giulio Vidotto; Gino Serra
Journal:  World J Psychiatry       Date:  2014-12-22

3.  Effect of memantine on C-reactive protein and lipid profiles in bipolar disorder.

Authors:  Hui Hua Chang; Po See Chen; Tzu-Yun Wang; Sheng-Yu Lee; Shiou-Lan Chen; San-Yuan Huang; Jau-Shyong Hong; Yen Kuang Yang; Ru-Band Lu
Journal:  J Affect Disord       Date:  2017-06-09       Impact factor: 4.839

Review 4.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

5.  Comparing clinical responses and the biomarkers of BDNF and cytokines between subthreshold bipolar disorder and bipolar II disorder.

Authors:  Tzu-Yun Wang; Sheng-Yu Lee; Shiou-Lan Chen; Yun-Hsuan Chang; Liang-Jen Wang; Po See Chen; Shih-Heng Chen; Chun-Hsien Chu; San-Yuan Huang; Nian-Sheng Tzeng; Chia-Ling Li; Yi-Lun Chung; Tsai-Hsin Hsieh; I Hui Lee; Kao Chin Chen; Yen Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

6.  The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism.

Authors:  Sheng-Yu Lee; Tzu-Yun Wang; Shiou-Lan Chen; Yun-Hsuan Chang; Po-See Chen; San-Yuan Huang; Nian-Sheng Tzeng; Liang-Jen Wang; I Hui Lee; Kao Chin Chen; Yen Kuang Yang; Yi-Hsin Yang; Ru-Band Lu; Cheng-Sheng Chen
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

Review 7.  The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.

Authors:  Johanna Taylor; Brendon Stubbs; Catherine Hewitt; Ramzi A Ajjan; Sarah L Alderson; Simon Gilbody; Richard I G Holt; Prakash Hosali; Tom Hughes; Tarron Kayalackakom; Ian Kellar; Helen Lewis; Neda Mahmoodi; Kirstine McDermid; Robert D Smith; Judy M Wright; Najma Siddiqi
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

8.  The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial.

Authors:  Victoria Omranifard; Fatemeh Rajabi; Maryam Mohammadian-Sichani; Mohammad Maracy
Journal:  Adv Biomed Res       Date:  2015-09-28

9.  The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.

Authors:  Ting-Ting Chang; Shiou-Lan Chen; Yun-Hsuan Chang; Po-See Chen; Chun-Hsien Chu; Shih-Heng Chen; San-Yuan Huang; Nian-Sheng Tzeng; Liang-Jen Wang; Tzu-Yun Wang; Chia-Ling Li; Yi-Lun Chung; Tsai-Hsin Hsieh; I-Hui Lee; Kao-Ching Chen; Yen-Kuang Yang; Jau-Shyong Hong; Ru-Band Lu; Sheng-Yu Lee
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Evaluation of the Effect of Memantine Supplementation in the Treatment of Acute Phase of Mania in Bipolar Disorder of Elderly Patients: A Double-blind Randomized Controlled Trial.

Authors:  Victoria Omranifard; Mohammad Javad Tarrahi; Shima Sharifi; Mojgan Karahmadi
Journal:  Adv Biomed Res       Date:  2018-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.